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Abstract
Background/Aim. Cardiovascular disease imposes a
burden to society in terms of mortality, morbidity and
economic losses. The aim of this study was to estimate the
economic burden of cardiovascular disease in Serbia in
2009 from the perspective of the society. Methods. For
the purpose of the study cardiovascular disease was de-
fined by the International Classification of Diseases, 10th
revision, as the following diagnosis: hypertension, coro-
nary heart disease, cardiomyopathy, heart failure and cere-
brovascular disease. The prevalence, top-down method
was used to quantify the annual cardiovascular costs. Pro-
ductivity losses were estimated using the human capital
approach and the friction cost method. A discount rate of
5% was used to convert all future lifetime earnings into
the present value. Results. The total direct costs of car-
diovascular disease in 2009 were € 400 million. The results
showed that more than half a million working days were
lost due to incapacity resulting from cardiovascular dis-
eases, yielding the € 113.9 millon. The majority of total
costs (€ 514.3 million) were for: medication (29.94%),
hospital days (28.97%) and hospital inpatient care – surgi-
cal and diagnostic interventions (17.84%). The results were
robust to a change in 20% of volume or the unit price of
all direct and indirect cost and to discount rate 2% and
10%. Conclusions. The total cardiovascular disease costs
in 2009 represented approximately 1.8% of the Serbian
gross domestic product. The results of the study would be
valuable to health policy makers to bridge the gap between
invested resources and needs, in order to improve cardio-
vascular disease outcomes.
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Apstrakt
Uvod/Cilj. Kardiovaskularne bolesti predstavljaju teret za
društvo u smislu mortaliteta, morbiditeta i ekonomskih gu-
bitaka. Cilj ove studije bio je procena ekonomskog znaÿaja
kardiovaskularnih bolesti u Srbiji u 2009. godini iz perspek-
tive društva. Metode. Za potrebe istraživanja, kardiovasku-
larne bolesti su definisane pomoýu  MeĀunarodne klasifika-
cije bolesti, 10. revizija, kao sledeýe dijagnoze: hipertenzija,
koronarne bolesti, kardiomiopatija, srÿana insuficijencija i
cerebrovaskularne bolesti. Korišýen je top-down metod, bazi-
ran na prevalenciji, kako bi se kvantifikovali godišnji kardio-
vaskularni troškovi. Troškovi smanjene produktivnosti su
procenjeni korišýenjem dva pristupa: pristup ljudskom ka-
pitalu (human capital approach) i metod frikcionih troškova
(friction cost method). Za obraÿunavanje troškova u sadašnju
vrednost korišýena je diskontna stopa od 5%. Rezultati.
Ukupni direktni troškovi kardiovaskularnih bolesti u 2009.
godini iznosili su 400 miliona evra. Rezultati pokazuju da je
više od pola miliona radnih dana izgubljeno zbog nesposo-
bnosti usled kardiovaskularnih bolesti, dajuýi ukupno 113,9
miliona evra indirektne troškove. Veýina ukupnih troškova
(514,3 miliona evra) bili su za: lekove (29,94%), hospitaliza-
ciju (28,97%) i bolniÿko leÿenje – hirurške intervencije i di-
jagnostiku (17,84%). Rezultati su bili robusni na promene
od 20% u volumenu ili ceni pojedinih kategorija troškova,
kao i na primenjenu diskontnu stopu od 2% i od 10%. Za-
kljuÿak. Ukupni troškovi kardiovaskularnih bolesti u 2009.
godini su predstavljali oko 1,8% bruto domaýeg proizvoda.
Rezultati studije su znaÿajni za kreiranje zdravstvene politike
i premošýavanja jaza izmeĀu uloženih sredstava i potreba, a
u cilju poboljšanja ishoda kardiovaskularnih bolesti.
Kljuÿne reÿi:
kardiovaskularne bolesti; zdravstvena zaštita, troškovi;
srbija.
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Introduction
Cardiovascular disease (CVD) imposes a burden to so-
ciety in terms' of mortality and morbidity, as well as an eco-
nomic impact. Management of CVD consumes a large
amount of healthcare resources. In America nearly 2,400
Americans die of CVD each day, an average of one death
every 37 seconds 1. CVD mortality in Eastern European
countries is much higher than the European average as it
reaches a value of 650 deaths per 100,000 in some coun-
tries 2 CVD dominated the burden of premature mortality in
Serbia (48%) with almost 400,000 years of life lost 3.
Cost of illness (or burden of disease) analysis involves
identification, measurement and valuation of resources related
to the illness, in this case CVD. The economic burden of CVD
consists of direct and indirect costs. Direct costs are associated
with hospitalisations, physician visits, rehabilitation services
and medications. Indirect costs represent losses to the econ-
omy due to premature mortality and morbidity, resulting in
lost economic production and consumption and the associated
effect on the functioning of the economy. The total costs of
CVD in the European Union were over 168 billion Euros in
2003, of which direct healthcare costs represented 62% 4.
National health authorities have postulated in their re-
port 5 that intensive research work is needed in the field of
CVD, particularly the impact of hypertension and its major
complications. Therefore, the purpose of this study was to
estimate the economic burden of cardiovascular disease in
Serbia in 2009 from the perspective of the society.
Methods
For the purpose of the study CVD was defined by the
International Classification of Diseases, 10th revision as the
following diagnosis: hypertension (I10–I15), coronary heart
disease (I20–I25), cardiomyopathy (I42), heart failure (I50)
and cerebrovascular disease (I60–I69). The method of
prevalence was used to quantify the annual CVD costs for
the total Serbian population in 2009 6. The analysis was per-
formed from the societal perspective including direct
healthcare costs, as well as indirect costs associated with
productivity loss due to morbidity or premature death which
were estimated.
We employed a top-down approach, using aggregate
data on morbidity, doctor visits at primary care, hospitalisa-
tions, medications utilisation, rehabilitations and mortality.
This approach was previously developed by Liu et al. 7 to
estimate economic burden of coronary heart disease. Pro-
ductivity losses were estimated using the human capital ap-
proach and the friction cost method 8. All costs were ex-
pressed in Euros (€), using the 2009 average exchange rate to
convert Serbian dinar (RSD) to the € (€1 = 94.12 RSD) 9.
Healthcare direct costs
Direct costs include the value of medical care resources
used to treat a disease. Healthcare costs were calculated by
assessing the value of resources used by patients for detec-
tion, treatment and rehabilitation of CVD.
The following items of healthcare service were in-
cluded: primary care provided by general practice; emer-
gency care; hospital care; diagnostic and surgical procedures;
rehabilitation services and medication treatment.
The number of patients visits to general practice re-
garding CVD was obtained from the Republic Institute for
Health Insurance (RIHI). The total number of hospital emer-
gency visits and hospitalisations were provided by the RIHI;
the average length of stay in hospital due to CVD was eight
days. The number of surgical interventions: percutaneous
transluminal coronary angioplasty (PTCA), coronary artery
bypass grafting (CABG) and coronography was also ob-
tained from RIHI, due to their complete coverage by the
RIHI. The number of diagnostic procedures was estimated
based on the prevalence of the given CVD and the current
clinical practice and guidelines in Serbia 10–13. The number of
rehabilitations was obtained from the Republic Institute for
Public Health; the average length of stay at the rehabilitation
unit was 20.5 days. Utilisation of the medications in hospital
and ambulatory settings aimed at prevention and treatment of
CVD was provided from the RIHI. Data regarding the utili-
sation were considered for the following Anatomical Thera-
peutic Chemical (ATC) classification system medicines
groups: B01 (antitrombotic agents), C01 (cardiac therapy),
C02 (antihypertensives), C03 (diuretics), C07 (beta blocking
agents), C08 (calcium channel blockers), C09 (agents acting
on renin-angiotensin system) and C10 (serum lipid reducing
agents).
The values of resources used were calculated by multi-
plying the resource quantities used in healthcare services for
management of CVD with their unit costs. All costs are de-
rived from the RIHI price list. The RIHI is a leading health
care payer, responsible for the health care of almost the en-
tire Serbian population (7.3 million). Hospitalisation daily
costs are calculated as the average value of days spent in
cardiovascular, neurological and neurosurgical unit, due to
the fact that the RIHI charges hospitalisation cost per diem.
Costs for a diagnostic procedures, both cerebrovascular dis-
ease and coronary heart disease, were calculated as the num-
ber of units consumed multiplied by the sum of different di-
agnostic procedures applied for given disease (e.g. neuro-
logical exam, computed tomography scan, magnetic reso-
nance imaging of the head, basic analysis of blood, bio-
chemical analysis of C-reactive protein, creatine kinase,
electrocardiogram, etc.). The costs of rehabilitation were cal-
culated as the average cost per day spent in rehabilitation
centres, multiplied with the average length of stay (20.5) and
the number of rehabilitation procedures. For ambulatory pre-
scribed medicines we included the pharmacy mark-up and
value added tax.
Healthcare indirect costs
Indirect costs included forgone earning related to mortal-
ity and morbidity due to CVD which were estimated using the
human capital approach. The indirect cost from mortality was
estimated considering the following: the number of premature
deaths due to CVD 14, the number of working years left till re-
tirement (65 years of age for men, 60 for women) 15, unem-
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ployment rate and the 2009 average earnings 16. We also cal-
culated the productivity loss in retirement based on predicted
years spent in retirement, life expectancy, and 2009 average
pension earnings.
The value of indirect cost from morbidity was estimated
as total number of days lost from work obtained from the
RIHI multiplied by the average daily earnings 16. According
to the current legislation 17, the first 30 sick days are paid by
the employer, additional sick days are charged to RIHI. Thus
we estimated the number of employers’ paid sick days as the
total number of persons for which the RIHI paid sick allow-
ances multiplied by 30 days. The authors did not find any
way of estimate the number of days lost due to morbidity
paid by employers not followed by the RIHI coverage.
Due to the fact that an estimate of lost production using
the human capital approach tends to be overestimated, we
also apply the friction cost method. In this case, production
losses are calculated during “the friction period” (time be-
tween the start of absence from work and replacement). This
is estimated to be about 90 days 18, 19. The friction period
adjusted productivity loss was calculated by multiplying the
unadjusted productivity loss, obtained as described above, by
the friction period (90 days) and then dividing this product
by the average duration of work incapacity (calculated in this
study, for CVD patient). A discount rate of 5% was used to
convert all future lifetime earnings into the present value 20.
Sensitivity analysis
To examine the robustness of the results we performed
one-way sensitivity analyses. We assessed the change in the
estimated total cost of CVD resulting from a 20% change in
the volume or the unit price of all direct and indirect costs;
the 20% change was based on the cost of illness study con-
ducted in EU 4. The effect of discounting on indirect costs
was assessed using the rates of 2% and 10%. All analyses
were performed using the Microsoft Excel.
Results
In 2009 women were diagnosed more often with CVD
than men (54% vs 46%). There were 338,279 patients diag-
nosed with hypertension; 505,358 patients with coronary
heart diseases; 221,663 patients with cardiomyopathy;
61,713 patient diagnosed with heart failure and 187,564 pa-
tient with cerebrovascular disease. Most of the diagnosed
diseases occurred in patients aged over 70 (Figure 1).
Direct costs
The total direct costs of CVD in 2009 were € 400 mil-
lion (Table 1). Hospitalisation and surgical and diagnostic
procedures applied to hospitalised patients accounted for €
240.7 million, or 60.13% of the direct costs. The majority of
costs attributable to surgical and diagnostic procedures were
allocated on diagnostic of cerebrovascular sequel (25.48% of
costs allocated on surgical and diagnostic procedures) and
PTCA (30.77% of costs allocated on surgical and diagnostic
procedures). Medication treatment accounted for 38.46% of
total direct costs (€ 154 million). Of these costs, 87.2% was
for prescription medicine covered by the RIHI used by out-
patients. Physician visits at primary care and rehabilitation
accounted just for 0.83% and 0.58%, respectively, of total di-
rect costs.
Indirect costs
The results showed that more than a half million work-
ing days were lost due to incapacity resulting from CVD
(Table 2). Cerebrovascular and coronary heart diseases
caused the longest absence from work, on average, 112.8
days and 100.7 days, respectively. The average length of in-
capacity for all CVD patients was 95 days. The production
losses due to CVD morbidity estimated using the human
capital approach were € 11.6 million; with the friction cost
method the estimate was lower at € 11 million. According to
Fig. 1 – Number of patients diagnosed with cardiovascular diseases according to age. In brackets are the diagnoses defined
by the International Classification of Disease, 10th revision.
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the results, more than 7100 working years were lost from
CVD; 74% of these years lost were from deaths in men. Of
all working years lost in men 83.05% were in the 40–59 year
age range; in women 74.92% of the working years lost were
from deaths in the 40–59 year age range. The mortality costs
due to CVD were estimated to be € 104.4 million. However,
after adjustment for friction period estimate fell to € 102.9
million.
Total costs
Table 3 shows the total costs of CVD for Serbia in
2009. The total costs resulted in € 514.3 million; most of
these costs were used for medication (29.94%), hospital days
(28.97%) and hospital inpatient care – surgical and diagnos-
tic interventions (17.84%). Indirect costs (mortality and
morbidity) accounted for 22.15% of total costs.
Table 1
The direct costs of cardiovascular disease (CVD)
Direct costs Number ofunits
Average cost
per unit (€)
Average stay
(days) Total cost (€)
Doctor (GP) visit at clinic 1 596 638 2.07 3 312 193
Hospitalisations due to CV complications 521 514 35.71 8 149 000 960
Interventions due to CV complications
PTCA (without stent) 13 500 1 455.79 19 653 171
drug eluting stent (DES) 6 750 1 058.23 7 143 042
bare metal stent (BMS) 6 750 211.65 1 428 638
Coronography 18 300 494.96 9 057 839
By-pass revascularisation; graft (CABG) 4 800 3 083.54 14 801 003
Diagnostic procedures for cerebrovascular disease* 146 024 160.04 23 369 984
Diagnostic procedures for coronary heart disease† 521 514 31.22 16 280 080
Rehabilitation due to CV complications 9 695 11.69 20.5 2 322 803
Medication treatment
antitrombolytic medicine (utilised in hospital) 1 821 787.45 4 330 162
outpatient reimbursed medicine (covered by
RIHI) 36 630 948.55 130 490 385
outpatient medicine (patient participation) 36 630 948.55 19 160 657
Total direct cost (€) 400 350 917
*Diagnostic procedures for cerebrovascular disease include: neurological exam, computed tomography (CT) scan, and magnetic resonance imaging (MRI)
of the head;  †diagnostic procedures for coronary heart disease include: basic analysis of blood, additional analysis of C-reactive protein (CRP), creatine
kinase (CK), myoglobin, and troponin-I, echocardiogram, electrocardiogram, and ergometry; GP – general practitioner; CV – cardiovascular; PTCA –
percutaneous transluminal coronary angioplasty; CABG – coronary artery bypass grafting; RIHI – Republic Institute for Health Insurance.
Table 2
The indirect costs of cardiovascular disease
Indirect costs Number ofunits
Average cost
per unit (€) Total cost (€)
Mortality
working years lost (men) 5 270.3 5 628.6* 19 738 507
working years lost (women) 1 857.7 5 628.6* 7 279 430
years lost in retirement (men) 8 693 2 523.6† 20 246 645
years lost in retirement (women) 26 080 2 523.6† 55 617 209
Morbidity (number of days lost from work)
RIHI paid 353 130 22.3 7 472 293
employer paid 168 720 22.3 3 570 145
Total indirect cost (€) 113 924 229
*Average annual earnings in 2009. For all future years the values of annual earning were discounted at 5% depending on the age of death; †Average
annual pension in 2009. For all future years the values of annual pension were discounted at 5% depending on the age at which death occurred.
Table 3
The total costs of cardiovascular disease
Type of costs Value (€) Percentage of total cost (%)
Direct costs
doctor (GP) visit at clinic 3 312 193 0.64
hospitalisation 149 000 960 28.97
surgical and diagnostic procedures 91 733 757 17.84
rehabilitation 2 322 803 0.45
medication treatment 153 981 203 29.94
Total direct cost 400 350 917 77.85
Indirect costs
mortality 102 881 791 20.00
morbidity 11 042 438 2.15
Total indirect cost 113 924 229 22.15
Total costs (€) 514 275 146 100
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Sensitivity analysis
The baseline estimate of total cost related to CVD was
not sensitive to changes in the input variables (Figure 2).
A change of 20% in volume or cost of hospitalisation
and prescription medicine produced the largest variation in
the baseline estimate of total cost of ± 5.79% and ± 5.07%,
respectively. Regarding the variables included in indirect
costs, the largest impact on total cost had 20% change in the
number of years lost in retirement for women (± 2.16%) and
change in discount rate. When a discount rate of 2% was ap-
plied, the baseline estimate changed for 2.31%; with the rate
10%, the total cost decline for - 2.80%. Changes in all other
variables produced very small effects on the total cost esti-
mate (between 0.06% and 1.03%).
Discussion
CVDs are a costly group of diseases to the health care
system. In 2009, the average CVD direct costs per patient
were over € 300. The results of the direct costs of CVD show
that more than 60% of the costs are attributable to hospitali-
sation and surgical/diagnostic procedures, while medication
treatment represented over 38% of the direct costs. Primary
care, which to some extent can be considered as preventive
medicine, accounts only for 0.83% of direct costs. In the
majority of studies on evaluation of economic burden of
CVD, hospital costs were the most expensive direct category,
with the values of 50–66% of total direct cost, followed by
pharmaceutical expenditures 4, 7, 21, 22. On the other hand,
Maetzel et al. 23 showed that 51.2% of direct costs in hyper-
tension were attributable to drugs, and only 20% to hospitali-
sation. Primary care accounted for only 8.8% in direct costs
in EU, with significant variation between countries, from
0.7% in Greece to 15.9% in Germany 4.
The estimated total indirect costs of CVD in Serbia
were almost € 114 million, with more than 90% attributable
to mortality. The cost of CVD in EU revealed that almost
70% of indirect costs are attributable to mortality; in some
EU countries, like Latvia, mortality represented 90.63% 4.
The total cost of CVD in Serbia was estimated to be
over € 514 million. Only a quarter (22.15%) of total cost was
estimated to be indirect cost (Table 3). In contrast, studies
conducted in UK, Canada, Finland and Mexico 7, 21, 22, 24
noted that much higher percent (in some cases over 50%) of
total cost is attributable to indirect costs. Such difference
could be explained by much lower average earning than in
the above mentioned, Western market economics. Bloom et
al. 25, in the review article of published cost-of-illness studies
on US populations, estimated that more than 48% of total
cost was attributable to indirect costs. A study by Leal et
al. 4, showed that daily and annual earnings in newer EU
countries (like Estonia, Latvia or Lithuania) in 2003, were
more than eight times lower than in older EU countries.
Similar results were observed in other transition countries,
after conducting the different cost of illness studies 26, 27. The
magnitude of the total costs devoted to CVD prevention and
treatment can be best represented as a % of gross domestic
product (GDP). According to our results, total cost of CVD
comprises approximately 1.78% of the total Serbian GDP 15.
In 2009 the total CVD cost was 3.37% of the total American
GDP 1. On the other hand, results of study conducted in
China in 2003, showed that 0.62% of the China GDP was
attributable to direct costs only 28.
In Serbia, women were diagnosed more often with
CVD, primarily coronary heart disease. Similar results were
shown in other studies 1, 23 where the prevalence of CVD was
higher in women. As it would be expected the majority of di-
agnosed patients were older than 70 years. The prevalence of
CVD increases with age, from 38.2% in the age group 40–59
to 82.6% among those aged 80 years or older 1.
A sensitivity analysis indicates that volume or cost of
hospitalisations and medicines are components which are
Fig. 2 – One-way sensitivity analyses of direct and indirect costs resulting from a ± 20% change in the volume or the unit
price of all factors, and discount rates of 2% and 10%. The sensitivity analyses of the factors that resulted with an change
in total cost estimate below ± 0.5% are not shown.
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most likely to affect estimated total cost but the overall im-
pact is small, less than 6% on total cost estimate (Figure 2).
This study has limitations because estimates of costs are
likely to be underestimated. The authors did not include pre-
ventive actions like anti-smoking campaigns in the analysis,
because of unavailability of the quantity of promotion activi-
ties and the amount of money devoted to them in Serbia. A
study on coronary heart disease costs in UK 7 estimated that
less than 0.002% of total cost was attributable to prevention,
so the authors believe that this omission would not affect our
results substantially.
The authors analysis also did not consider the cost of
patient travel expenses. However these costs make up only a
small percentage of CVD costs 29. The out-of-pocket expen-
ditures for different Over the Counter (OTC) medicines or
dietary supplements for CVD were not considered in the
analysis due to no published data regarding the consumption.
As the authors postulated in the Methods section the sick
leave less than 30 days was not included in the study due to
the absence of the data. Also, since we used the prevalence,
top-down approach, productivity losses were estimated as
average earning ad pension. The cost estimate would proba-
bly be different if patient population was divided into sub-
groups according to the education level and socioeconomic
status. However, due to the absence of these data, a more ac-
curate estimate was impossible.
Authors did not focus on the clinical guidelines and
protocols. It would be interesting for further research to
evaluate compliance of the prescribers with the clinical
guidelines, especially with the recommendations regarding
antihypertensive   medications, since our study showed that
almost 30% of a total cost is attributable to medications cost.
In spite of its limitations, this is the first cost of illness
study that estimated direct and indirect costs associated with
CVD in Serbia. Cost of illness studies cannot determine
whether healthcare system is spending too much in a par-
ticular area, in this case CVD, but it has the potential to
identify main cost drivers of the disease. This helps in allo-
cating scant health care resources efficiently, and conse-
quently leads to improved clinical and economic outcomes,
reducing the morbidity and mortality of CVD, resulting with
the substantial financial savings. Also, the magnitude and
pattern of expenditure can guide research priorities and deci-
sion makers in the development of better action plan in order
to decrease the burden of CVD.
Conclusion
CVD is a high costly group of diseases with the heavy
burden to society. The total costs in 2009 represented ap-
proximately 1.8% of the Serbian GDP. The authors believe
that the results of this study would be of special interest for
national health policy makers to bridge the gap between in-
vested resources and needs, in order to improve CVD out-
comes. High efforts should be made and taken to prevent
CVD in order to reduce medical costs and productivity losses
to society.
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